Astrocyte

Cerevance Announces Presentation at the SFN Neuroscience 2023 Annual Meeting

Retrieved on: 
Tuesday, November 7, 2023
Potassium, Gene expression, Therapy, Pathology, KCNJ10, CNS, Society, Disease, Date, Cerev Del, Annual general meeting, Astrocyte, Central nervous system, Vaccine, Neuroscience

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing novel precision therapeutics for central nervous system (CNS) diseases, today announced plans to present a poster presentation at the Neuroscience 2023 Annual Meeting presented by the Society for Neuroscience, taking place in Washington, D.C., November 11 – 15th, 2023.

Key Points: 
  • BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing novel precision therapeutics for central nervous system (CNS) diseases, today announced plans to present a poster presentation at the Neuroscience 2023 Annual Meeting presented by the Society for Neuroscience, taking place in Washington, D.C., November 11 – 15th, 2023.
  • Overview: Gene expression relevant to human disease pathology can be observed using Cerevance’s proprietary NETSseq platform.
  • Data from this approach demonstrated that KCNJ10 is expressed in astrocytes from post-mortem brain tissue of Alzheimer’s and Parkinson’s disease donors and is increased in disease.
  • Session and Date and Time: Potassium Channels; November 15th, 8am – 12pm ET

ZyVersa Therapeutics Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating That Inflammasome ASC Inhibitor IC 100 Attenuates the Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neur

Retrieved on: 
Wednesday, November 1, 2023
Intellectual disability, Inflammasome, EAE, ASC, Mouse, NLRP3, Microglia, Neuroprotection, Phenotype, Inflammation, Research, Brain, Neurotoxicity, Neuroinflammation, Immunomodulation, M1, Molecular neuroscience, Multiple sclerosis, Spinal cord, Astrocyte, Disability, Therapy, Neuroscience, Super Meat Boy, MS, Central nervous system, Pharmaceutical industry

ZyVersa is developing Inflammasome ASC Inhibitor IC 100, designed to inhibit formation of multiple types of inflammasomes and their associated ASC specks to attenuate initiation and perpetuation of damaging inflammation.

Key Points: 
  • ZyVersa is developing Inflammasome ASC Inhibitor IC 100, designed to inhibit formation of multiple types of inflammasomes and their associated ASC specks to attenuate initiation and perpetuation of damaging inflammation.
  • Key findings showed that NLRP3 inflammasome inhibition:
    Ameliorated pathological changes in the spinal cord and neuron damage in the brain of MS mice.
  • “It is encouraging that the research published in Molecular Neurobiology substantiates our published MS data with Inflammasome ASC Inhibitor IC 100, providing support for its use as a potential therapeutic option.
  • By inhibiting ASC, IC 100 blocks formation of NLRP3 and other types of inflammasomes to block initiation of the inflammatory cascade.

Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases

Retrieved on: 
Thursday, October 26, 2023
Fillit, Plasma, AD, Astrocyte, HD, MD, Conference, Brain, Dementia, Inflammation, Clinical trial, Encephalitis, Disease, Glial fibrillary acidic protein, Risk, Antibody, GFAP, Blood, Patient, Pharmaceutical industry, Medical imaging

The company now reports data indicating that pepinemab treatment significantly reduced blood levels of GFAP, a biomarker of reactive astrocytes, providing further evidence of the drug’s potential to reverse harmful astrocyte activation and brain inflammation.

Key Points: 
  • The company now reports data indicating that pepinemab treatment significantly reduced blood levels of GFAP, a biomarker of reactive astrocytes, providing further evidence of the drug’s potential to reverse harmful astrocyte activation and brain inflammation.
  • Astrocytes are key regulatory cells in the brain that, under conditions of brain injury or disease, switch from their normal supportive physiological functions to inflammatory activity that is believed to aggravate damage to brain tissue.
  • A committee convened by the Alzheimer’s Association has recently recommended GFAP as a leading blood-based biomarker of astrocytic activation and brain inflammation in AD.
  • Given the many physiological parallels between neurodegenerative processes in HD and AD, we believe that similar biological effects of pepinemab treatment are likely in the two indications.

Rodent Optic Nerve Head Wins the 49th Annual Nikon Small World Photo Microscopy Competition

Retrieved on: 
Tuesday, October 17, 2023
Paratriathlon, Nikon Instruments, Communication, Eye, Nikon Small World, Senior, Beauty, Diabetic retinopathy, Lions Eye Institute, Contract management, Disease, Diabetes, Friction, Blood, CRM, Person, Science, Retina, Astrocyte, Ophthalmic artery, Research, Pharmaceutical industry, Medical imaging

MELVILLE, N.Y., Oct. 17, 2023 /PRNewswire/ -- Nikon Instruments Inc. today unveiled the winners of the 49th annual Nikon Small World Photomicrography Competition. This year's first place prize was awarded to Hassanain Qambari, assisted by Jayden Dickson of the Lions Eye Institute, for his vivid image of a rodent optic nerve head showing astrocytes (yellow), contractile proteins (red), and retinal vasculature (green). The colorful image provides an important contribution to the study and reversal of diabetic retinopathy, which affects one in five persons with diabetes worldwide.1

Key Points: 
  • MELVILLE, N.Y., Oct. 17, 2023 /PRNewswire/ -- Nikon Instruments Inc. today unveiled the winners of the 49th annual Nikon Small World Photomicrography Competition .
  • The damaged blood vessels can swell and leak, which can cause blurry vision or total loss of eyesight.
  • "The Nikon Small World competition is great, as it showcases amazing work across many disciplines from around the world," said Qambari.
  • In addition to the top three winners, Nikon Small World recognized 83 photos out of thousands of entries from scientists and artists across the globe.

Research in the Special Issue of Journal of Pharmaceutical Analysis Uncovers Previously Unexplored Cellular Mechanisms

Retrieved on: 
Tuesday, October 17, 2023
Male, ICH, Myocardial infarction, IGF1, Stroke, Brain, Intracerebral hemorrhage, UPK3B (gene), JPA, Reactive oxygen species, Toxicity, ECM, Patient, Spatial analysis, PLX3397, Journal, Microglia, Mouse, Extracellular matrix, Dick's Picks Volume 13, Transcriptome, Astrocyte, Prognosis, Inflammation, Research, Medical imaging, Pharmaceutical industry, C3

This comprehensive understanding paves the way for them to uncover some intricate and previously unknown disease mechanisms.

Key Points: 
  • This comprehensive understanding paves the way for them to uncover some intricate and previously unknown disease mechanisms.
  • Three articles in the most recent special issue of the Journal of Pharmaceutical Analysis (JPA) discuss how single-cell and spatially resolved omics help unravel intercellular dynamics, aiding the development of novel therapeutic modalities.
  • The article was available online in February 2023 and published in Volume 13, Issue 8 of JPA in August 2023 .
  • Together, these articles enlighten us with a deeper understanding of cellular mechanisms at the single-cell and spatial levels, offering hope for improved treatment strategies in the future.

Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance

Retrieved on: 
Wednesday, September 6, 2023
Cognition, Rapunzel's Tangled Adventure (season 2), National academy, Human, PNAS, Microglia, Memory, Neurodegenerative disease, EAE, Prefrontal cortex, Brain, Research, NanoString Technologies, Gene expression, Multiple sclerosis, Astrocyte, Homeostasis, Harvard Medical School, Anti-CD3 monoclonal antibody, Publication, Animal, Patient, Neurology, Immune system, Mab, Mouse, Hospital, FDA, AD, Phenotype, IND, Alzheimer's disease, Hippocampus, Disease, Vaccine, Medical imaging, Pharmaceutical industry, Brigham

Remarkably, we found this benefit occurred independent of reduction of amyloid beta plaque in the brain.

Key Points: 
  • Remarkably, we found this benefit occurred independent of reduction of amyloid beta plaque in the brain.
  • This represents a unique approach to treating Alzheimer’s disease that could also potentially be employed in combination with anti-amyloid therapy.
  • Alzheimer's disease is a neurodegenerative disease characterized by amyloid beta (Aβ) plaques, neurofibrillary tangles, and microglial activation.
  • In this study, mice were treated three times a week with intranasal anti-CD3 for five months and compared against isotype control or saline.

Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 14, 2023
PDAC, Completeness, Rochester, Trastuzumab, Pathology, Merck Group, Cash, Astrocyte, Patient, FCMI, Observation, H. Lee Moffitt Cancer Center & Research Institute, Private placement, Three Months, Eurosport 1, University, Brain, Research, Lecanemab, TME, Motivation, Drug discovery, Neoplasm, FDA, B cell, Safety, Cognition, Neuron, ICI, G protein-coupled receptor, Metastatic breast cancer, DC1, Cancer, Lung cancer, CCR8, Immunotherapy, Antibody, PFS, ARIA, Publication, MBC, Biomarker, Microglia, SEMA4D, Security, ORR, HD, Head and neck cancer, Drug development, Nature, SIGNAL, Avelumab, Neurodegenerative disease, Pfizer, CO, Breast cancer, Pharmaceutical industry, Medical imaging, Vaccine, Cryptocurrency, HNSCC, Merck

ROCHESTER, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update on progress in key programs. .

Key Points: 
  • Expect to Complete 12-months treatment in June, 2024
    ROCHESTER, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update on progress in key programs.
  • Over the last few months, Vaccinex achieved several important clinical milestones for pepinemab in both Alzheimer’s disease and Head and Neck Cancer.
  • In the first segment, completed on May 12, 2023, Vaccinex sold approximately 7.9 million shares of common stock for aggregate proceeds of $2.96 million.
  • For further details on Vaccinex’s financials, refer to its Form 10Q filed August 14, 2023 with the S.E.C.

Alzheimer's Drug Discovery Foundation Joins Astrocyte Pharmaceuticals’ $6M Pre-Series B Financing Round to Expand Development of Cerebroprotectant AST-004

Retrieved on: 
Friday, August 18, 2023
Biotechnology, Professional Services, Health, General Health, Pharmaceutical, Neurology, Mental Health, Research, Science, Clinical Trials, Finance, Fillit, Therapy, Face, Drug discovery, Astrocyte, Stroke, Brain, TBI, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Inflammation, Patient, Alzheimer's Drug Discovery Foundation, Traumatic brain injury, Medicine, Entrepreneurship, Pharmaceutical industry, Alzheimer's disease

Astrocyte Pharmaceuticals Inc. , a clinical-stage drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, announced an oversubscribed pre-Series B Bridge financing round of over $6M that was led by Dreavent Capital, and joined by the Alzheimer's Drug Discovery Foundation, and other investors.

Key Points: 
  • Astrocyte Pharmaceuticals Inc. , a clinical-stage drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, announced an oversubscribed pre-Series B Bridge financing round of over $6M that was led by Dreavent Capital, and joined by the Alzheimer's Drug Discovery Foundation, and other investors.
  • “There are millions of patients living with brain injuries worldwide who face limited treatment options for these devastating conditions,” said William Korinek, Ph.D, CEO, Astrocyte Pharmaceuticals.
  • “Astrocyte has assembled an exceptional team of experts that are conducting research of the highest quality at every step,” commented Gorka Fius, CEO at Dreavent Capital who led the investment round.
  • “Finding innovative ways to target inflammation in the brain will play an important role in the future of combination therapy and precision medicine for Alzheimer's disease,” said Howard Fillit, M.D., Co-Founder and Chief Science Officer, Alzheimer's Drug Discovery Foundation.

Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023

Retrieved on: 
Thursday, July 20, 2023
PK, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GFAP, Glial fibrillary acidic protein, Clinical trial, SC, The New England Journal of Medicine, Pathology, PET, Brain, Biomarker, Clarity, Plasma, AAIC, Fluid mechanics, Amyloid, Astrocyte, Neurogranin, Lecanemab, AD, FDA, Conference, Food, Safety, Biogen, Medical imaging, Pharmaceutical industry, Alzheimer's disease, CSF

This analysis, and the latest findings on the lecanemab subcutaneous (SC) formulation currently under development, were presented at the Alzheimer's Association International Conference (AAIC) 2023.

Key Points: 
  • This analysis, and the latest findings on the lecanemab subcutaneous (SC) formulation currently under development, were presented at the Alzheimer's Association International Conference (AAIC) 2023.
  • The U.S. Food and Drug Administration (FDA) granted traditional approval for LEQEMBI for the treatment of Alzheimer's disease (AD) on July 6, 2023.
  • In an exposure/bioavailability and modeling study comparing intravenous (IV) and subcutaneous (SC) dosing of lecanemab, the bioavailability of SC dosing of lecanemab was shown to be approximately 50% of that of IV dosing.
  • Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

Phyllodulcin Could be a Potential Candidate for Treating Alzheimer's Disease, Find Sahmyook University Researchers

Retrieved on: 
Friday, July 28, 2023
Rapunzel's Tangled Adventure (season 2), Male, Biomedicine, Pathology, Deficit spending, Traffic barrier, Brain, Research, Cell, Astrocyte, Assistant, Dementia, Polyphenol, Sahmyook University, Amnesia, Mouse, Microglia, Neurotoxicity, Alzheimer's disease, Hippocampus, Disease, Pharmaceutical industry, Vaccine

Brain lesions caused by the aggregation of amyloid β (Aβ) and neurofibrillary tangles are believed to be the main cause of AD.

Key Points: 
  • Brain lesions caused by the aggregation of amyloid β (Aβ) and neurofibrillary tangles are believed to be the main cause of AD.
  • While many drugs targeting Aβ have been developed, they have failed to demonstrate efficacy in clinical trial studies.
  • Moreover, the use of approved antibody drugs is associated with high costs of treatment and uncertain efficacy.
  • Therefore, developing a simple and efficient drug that targets Aβ for the treatment of AD is needed.